AML Epigenomic Risk remained as an independent predictor of OS (HR = 3.86; 95% CI = 2.74, 5.44; P < 0.0001) (Fig. 4c) and EFS (HR = 1.78; 95% CI = 1.40, 2.27; P = 0.0009) (Fig. 4d) in multivariable analysis after adjusting for MRD1 status, risk group, FLT3 status, leucocyte counts at diagnosis, BM blast % at diagnosis, and age groups in discovery cohort. This evidence concerns the gene FLT3 and acute myeloid leukemia.